Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer

Overview

Journal Curr Treat Options Oncol

Date 2025 Jan 22

PMID 39841387

Authors

Yili Shen

Zhicong Liu

Yi Chen

Xuefei Shi

Shunli Dong

Bin Wang

Affiliations

Soon will be listed here.

Abstract

Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immunotherapy to platinum-based chemotherapy offers sustained overall survival benefits and become the standard for the first-line setting of extensive-stage small-cell lung cancer. However, only a limited number of patients derive prolonged benefits. Although novel immunomodulatory agents and combination strategies are currently under investigation, identifying patients who are likely to obtain clinical benefits from this therapeutic approach is urgently needed. The modest therapeutic response to immunotherapy can be explained by various mechanisms. Traditional biomarkers do not guide immunotherapeutic decision-making in small-cell lung cancer. Notably, recent progress in the understanding of the molecular typing of small-cell lung cancer based on multi-omics data might bring new sights. This review summarizes the potential biomarkers for small-cell lung cancer immunotherapy based on clinical trials and preclinical studies. Moreover, important constraints in identifying biomarkers for small-cell lung cancer treatment are discussed.

References

Megyesfalvi Z, Gay C, Popper H, Pirker R, Ostoros G, Heeke S . Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023; 73(6):620-652. DOI: 10.3322/caac.21785. View

Cheng Y, Spigel D, Cho B, Laktionov K, Fang J, Chen Y . Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. N Engl J Med. 2024; 391(14):1313-1327. DOI: 10.1056/NEJMoa2404873. View

Liang J, Guan X, Bao G, Yao Y, Zhong X . Molecular subtyping of small cell lung cancer. Semin Cancer Biol. 2022; 86(Pt 2):450-462. DOI: 10.1016/j.semcancer.2022.05.010. View

Horn L, Mansfield A, Szczesna A, Havel L, Krzakowski M, Hochmair M . First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018; 379(23):2220-2229. DOI: 10.1056/NEJMoa1809064. View

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019; 394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. View

Goldman J, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D . Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2020; 22(1):51-65. DOI: 10.1016/S1470-2045(20)30539-8. View

Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G . Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022; 23(6):739-747. DOI: 10.1016/S1470-2045(22)00224-8. View

Rudin C, Awad M, Navarro A, Gottfried M, Peters S, Csoszi T . Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020; 38(21):2369-2379. PMC: 7474472. DOI: 10.1200/JCO.20.00793. View

Spigel D, Vicente D, Ciuleanu T, Gettinger S, Peters S, Horn L . Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol. 2021; 32(5):631-641. DOI: 10.1016/j.annonc.2021.01.071. View

10.

Owonikoko T, Park K, Govindan R, Ready N, Reck M, Peters S . Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. J Clin Oncol. 2021; 39(12):1349-1359. PMC: 8078251. DOI: 10.1200/JCO.20.02212. View

11.

Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P . Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. J Thorac Oncol. 2024; 19(7):1073-1085. DOI: 10.1016/j.jtho.2024.03.008. View

12.

Tu J, Liang H, Li C, Huang Y, Wang Z, Chen X . The application and research progress of anti-angiogenesis therapy in tumor immunotherapy. Front Immunol. 2023; 14:1198972. PMC: 10272381. DOI: 10.3389/fimmu.2023.1198972. View

13.

Wang J, Wang K, Yu Y, Lu Y, Xiao W, Sun Z . Self-improving generative foundation model for synthetic medical image generation and clinical applications. Nat Med. 2024; 31(2):609-617. DOI: 10.1038/s41591-024-03359-y. View

14.

Ahn M, Cho B, Felip E, Korantzis I, Ohashi K, Majem M . Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med. 2023; 389(22):2063-2075. DOI: 10.1056/NEJMoa2307980. View

15.

Carlisle J, Leal T . Advancing immunotherapy in small cell lung cancer. Cancer. 2023; 129(22):3525-3534. DOI: 10.1002/cncr.34977. View

16.

Burr M, Sparbier C, Chan K, Chan Y, Kersbergen A, Lam E . An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019; 36(4):385-401.e8. PMC: 6876280. DOI: 10.1016/j.ccell.2019.08.008. View

17.

Mahadevan N, Knelson E, Wolff J, Vajdi A, Saigi M, Campisi M . Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021; 11(8):1952-1969. PMC: 8338750. DOI: 10.1158/2159-8290.CD-20-0913. View

18.

He Y, Rozeboom L, Rivard C, Ellison K, Dziadziuszko R, Yu H . MHC class II expression in lung cancer. Lung Cancer. 2017; 112:75-80. DOI: 10.1016/j.lungcan.2017.07.030. View

19.

Hamilton G, Rath B . Immunotherapy for small cell lung cancer: mechanisms of resistance. Expert Opin Biol Ther. 2019; 19(5):423-432. DOI: 10.1080/14712598.2019.1592155. View

20.

Wang W, Hodkinson P, McLaren F, MacKinnon A, Wallace W, Howie S . Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate. Int J Cancer. 2012; 131(6):E928-37. DOI: 10.1002/ijc.27613. View